Literature DB >> 17176979

Investigating the existence of quantum metabolic values in non-Hodgkin's lymphoma by 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography.

Ching-yee Oliver Wong1, Joseph Thie, Kelly J Parling-Lynch, Dana Zakalik, Regina H Wong, Marianne Gaskill, Jeffrey H Margolis, Jack Hill, Ammar Sukari, Surya Chundru, Darlene Fink-Bennett, Conrad Nagle.   

Abstract

OBJECTIVES: To investigate the existence of quantum metabolic values in various subtypes of non-Hodgkin's lymphoma (NHL).
METHODS: Fifty-eight patients with newly diagnosed NHL and positron emission tomography (PET) performed within three months of biopsy were included. The standardized uptake value (SUV) from PET over the area of biopsy and serum glucose [Glc] were recorded. The group glucose sensitivity(G) for indolent and aggressive NHL was obtained by linear regression with ln(SUV) = G x ln[Glc] + C, where C is a constant for the group. Finally, the individual's glucose sensitivity (g) was obtained by g = {ln(SUV)-C}/ln[Glc], along with their means in various subtypes of NHL. To further investigate the influence of extreme [Glc] conditions, the SUVs corrected by the individually calculated g at various glucose levels, [Glc'] using SUV' =SUV x {[Glc']/[Glc]}(g), were compared to the original SUVs for both indolent and aggressive NHL.
RESULTS: The averaged g (=G) for aggressive was significant different from that for indolent NHL (-0.94 +/- 0.51 vs. +0.13 +/- 0.10, respectively, p < 0.00005). There were significant differences in SUV for [Glc] < 80 or >110 mg/dl for both types of NHL. Unlike overlap among SUVs between NHL subtypes, the g value clearly categorized them into two distinct groups with positive (near-zero) and negative g values (around -1) for the indolent and aggressive NHLs, respectively.
CONCLUSIONS: Distinct quantum metabolic values of -1 and 0 were noted in NHL. Aggressive NHL has a more negative value (or higher glucose sensitivity) than that of indolent and, thus, is more susceptible to extreme glucose variation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17176979     DOI: 10.1007/s11307-006-0074-z

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  20 in total

1.  Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation.

Authors:  Karoline Spaepen; Sigrid Stroobants; Patrick Dupont; Peter Vandenberghe; Johan Maertens; Guy Bormans; José Thomas; Jan Balzarini; Christine De Wolf-Peeters; Luc Mortelmans; Gregor Verhoef
Journal:  Blood       Date:  2003-02-27       Impact factor: 22.113

2.  Anatomy of SUV. Standardized uptake value.

Authors:  S C Huang
Journal:  Nucl Med Biol       Date:  2000-10       Impact factor: 2.408

3.  PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.

Authors:  Lale Kostakoglu; Morton Coleman; John P Leonard; Ichiei Kuji; Holly Zoe; Stanley J Goldsmith
Journal:  J Nucl Med       Date:  2002-08       Impact factor: 10.057

4.  Utility of FDG-PET scanning in lymphoma by WHO classification.

Authors:  Rebecca Elstrom; Liang Guan; Gary Baker; Khozaim Nakhoda; Jo-Anne Vergilio; Hongming Zhuang; Stephanie Pitsilos; Adam Bagg; Lisa Downs; Amit Mehrotra; Scott Kim; Abass Alavi; Stephen J Schuster
Journal:  Blood       Date:  2003-01-16       Impact factor: 22.113

5.  Glucose-normalized standardized uptake value from (18)F-FDG PET in classifying lymphomas.

Authors:  Ching-Yee Oliver Wong; Joseph Thie; Kelly J Parling-Lynch; Dana Zakalik; Jeffrey H Margolis; Marianne Gaskill; Jack Hill; Feng Qing; Darlene Fink-Bennett; Conrad Nagle
Journal:  J Nucl Med       Date:  2005-10       Impact factor: 10.057

6.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.

Authors:  R I Fisher; E R Gaynor; S Dahlberg; M M Oken; T M Grogan; E M Mize; J H Glick; C A Coltman; T P Miller
Journal:  N Engl J Med       Date:  1993-04-08       Impact factor: 91.245

7.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.

Authors:  G Jerusalem; Y Beguin; M F Fassotte; F Najjar; P Paulus; P Rigo; G Fillet
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

8.  Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma.

Authors:  H Schöder; J Meta; C Yap; M Ariannejad; J Rao; M E Phelps; P E Valk; J Sayre; J Czernin
Journal:  J Nucl Med       Date:  2001-08       Impact factor: 10.057

9.  18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT.

Authors:  N G Mikhaeel; A R Timothy; M J O'Doherty; S Hain; M N Maisey
Journal:  Leuk Lymphoma       Date:  2000-11

10.  Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.

Authors:  K Spaepen; S Stroobants; P Dupont; P Vandenberghe; J Thomas; T de Groot; J Balzarini; C De Wolf-Peeters; L Mortelmans; G Verhoef
Journal:  Ann Oncol       Date:  2002-09       Impact factor: 32.976

View more
  4 in total

1.  Time sensitivity: a parameter reflecting tumor metabolic kinetics by variable dual-time F-18 FDG PET imaging.

Authors:  Ching-yee Oliver Wong; Daniel Noujaim; Hungsen F Fu; Wen-sheng Huang; Cheng-yi S Cheng; Joseph Thie; Ishani Dalal; Chih-yung Chang; Conrad Nagle
Journal:  Mol Imaging Biol       Date:  2009-03-27       Impact factor: 3.488

2.  Correlating metabolic activity with cellular proliferation in follicular lymphomas.

Authors:  Bingfeng Tang; Jozef Malysz; Vonda Douglas-Nikitin; Richard Zekman; Regina Heather Wong; Ishmael Jaiyesimi; Ching-Yee Oliver Wong
Journal:  Mol Imaging Biol       Date:  2009-05-09       Impact factor: 3.488

3.  Revisiting the Marrow Metabolic Changes after Chemotherapy in Lymphoma: A Step towards Personalized Care.

Authors:  Bingfeng Tang; Malaykumar M Patel; Regina H Wong; Daniel Wood; Christiana O Wong; Dafang Wu; Pek Lan Khong; Ching Yee Oliver Wong
Journal:  Int J Mol Imaging       Date:  2011-09-28

4.  Implications of Ambient Glucose Variation on the Target-to-Background Ratio of Hepatic Tumors By (18)FDG-PET Imaging.

Authors:  Prashant Jolepalem; Lesley Flynt; John N Rydberg; Ching-Yee Oliver Wong
Journal:  J Clin Imaging Sci       Date:  2014-07-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.